FDA approves cancer drug using novel endpoint

The US Food and Drug Administration has used a novel endpoint to approve a new drug for prostate cancer. Measuring metastasis-free survival, the agency decided that the Janssen Pharmaceutical drug Erleada (apalutamide) is effective.